Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Genus plc ( (GB:GNS) ) is now available.
Genus plc reported strong financial performance for the year ending June 30, 2025, with a 5% increase in revenue in constant currency and a 24% rise in adjusted profit before tax. The company achieved significant strategic progress, including FDA approval for its PRRS Resistant Pig gene edit and the formation of a joint venture in China to accelerate growth and commercialization efforts. These developments are expected to enhance Genus’s market positioning and provide substantial growth opportunities, particularly in the porcine industry.
The most recent analyst rating on (GB:GNS) stock is a Buy with a £25.50 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Spark’s Take on GB:GNS Stock
According to Spark, TipRanks’ AI Analyst, GB:GNS is a Neutral.
Genus plc scores a 68, driven primarily by successful strategic initiatives and positive corporate events, including FDA approval for a key product. While technical analysis indicates strong momentum, caution is advised due to overbought signals. Financial performance and valuation reveal areas of concern, particularly in profitability and liquidity, warranting careful monitoring.
To see Spark’s full report on GB:GNS stock, click here.
More about Genus plc
Genus plc is a company that specializes in genetic improvement for livestock farmers and food producers, primarily in the dairy, beef, and pork sectors. The company offers products such as semen, embryos, and breeding animals with superior genetics to enhance production efficiency and quality. Genus operates globally under the trademarks ‘ABS’ for dairy and beef cattle and ‘PIC’ for pigs, with a competitive edge in proprietary breeding lines and biotechnology.
Average Trading Volume: 164,079
Technical Sentiment Signal: Buy
Current Market Cap: £1.7B
For an in-depth examination of GNS stock, go to TipRanks’ Overview page.